SightGlass Vision announced today that it received CE Mark approval in Europe for its eyeglasses for slowing myopia progression in children.
Palo Alto, Calif.-based SightGlass Vision touts its novel diffusion optics technology (DOT) spectacle lens products as the first of its kind to show success in a multi-center, randomized, controlled clinical trial to include options for myopia (nearsightedness) management.
In April, the company reported 12-month data from its Cypress clinical study that revealed a 74% reduction in myopia progression in both arms, plus a 50% reduction in axial length progression at 12 months in both arms as well, according to a news release from April 27.
“Our novel spectacle lenses designed to slow myopia progression in children have been hailed as a revolutionary innovation in the field of myopia management,” SightGlass Vision founder & CEO Thomas Chalberg said in a release today. “The CE Mark allowing European marketing authorization for our suite of DOT products is an important leap forward for our company, as we advance our mission to end myopia.
“We look forward to bringing to market a powerful and unique mechanism of action that we are confident will benefit children in the EU and other CE Mark geographies who live with myopia and are at risk from its vision-threatening complications.”